ADC: a deadly killer of platinum resistant ovarian cancer
Abstract Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their...
Saved in:
Main Authors: | Xu Cheng (Author), Ping Li (Author), Rongqi Jiang (Author), Enqing Meng (Author), Hao Wu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review
by: Hao Lin, et al.
Published: (2024) -
Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining
by: Haixia Li, et al.
Published: (2020) -
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2019) -
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
by: Huan Wu, et al.
Published: (2020) -
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014)